First Real-World Experience Administering Etranacogene Dezaparvovec Gene Therapy for People with Hemophilia B

被引：0
|
作者：
Ryan, Matthew L. [1 ]
Miller, Andrea [2 ]
O'Hearn, Patrick [2 ]
Desai, Vidhi Parikh [3 ]
机构：
[1] Green Bay Oncol, Green Bay, WI USA
[2] Hemophilia Outreach Ctr, Green Bay, WI USA
[3] CSL Behring, King Of Prussia, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] EARLY REAL-WORLD EXPERIENCE WITH EMICIZUMAB AND CONCOMITANT FACTOR VIII REPLACEMENT PRODUCTS IN ADULT, MALE PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
    Cafuir, L.
    Estrin, A.
    Chen, E.
    Hinds, D.
    Prince, P.
    Thorburn, J.
    Mead, H.
    Kempton, C.
    VALUE IN HEALTH, 2022, 25 (07) : S359 - S359
  • [42] Hazards of thrombolytic therapy for stroke: the real-world experience - Reply
    Bladin, C.
    Bray, J.
    Coughlan, K.
    INTERNAL MEDICINE JOURNAL, 2007, 37 (05) : 349A - 350
  • [43] The First Real-World Experience with Betibeglogene Autotemcel (beti-cel) Gene Therapy Treatment for Transfusion-Dependent β-Thalassemia (TDT)
    Kunz, Joachim B.
    Roth, Eva
    Mirza, Adil
    Greil, Johann
    Pavel, Petra
    Schmitt, Anita
    Schmitt, Michael
    Kunz, Alexander
    Kulozik, Andreas E.
    BLOOD, 2021, 138
  • [44] Meningococcal B vaccination: real-world experience and future perspectives
    Kuhdari, Parvane
    Stefanati, Armando
    Lupi, Silvia
    Valente, Nicoletta
    Gabutti, Giovanni
    PATHOGENS AND GLOBAL HEALTH, 2016, 110 (4-5) : 148 - 156
  • [45] Stable and durable factor IX levels over 4 years after etranacogene dezaparvovec gene therapy administration in a Phase 2b trial in patients with haemophilia B
    von Drygalski, A.
    Pipe, S. W.
    Giermasz, A.
    Gomez, E.
    Monahan, P. E.
    Le Quellec, S.
    HAEMOPHILIA, 2024, 30 : 53 - 53
  • [46] Real-World Experience with RTOG 0227 Induction for First Line Therapy of Primary CNS Lymphoma (PCNSL)
    Ahmed, Ramsha
    Anyanwu, Precious
    Shah, Nirav N.
    Hamadani, Mehdi
    Longo, Walter
    Devata, Sumana
    Pruett, Julie
    Connelly, Jennifer
    Bovi, Joseph
    Siker, Malika
    Schultz, Christopher
    Fenske, Timothy S.
    BLOOD, 2023, 142
  • [47] Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
    Ay, Cihan
    Perschy, Leonard
    Rejtoe, Judit
    Kaider, Alexandra
    Pabinger, Ingrid
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2763 - 2771
  • [48] Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
    Cihan Ay
    Leonard Perschy
    Judit Rejtö
    Alexandra Kaider
    Ingrid Pabinger
    Annals of Hematology, 2020, 99 : 2763 - 2771
  • [49] Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B
    Pipe, Steven
    van der Valk, Paul
    Verhamme, Peter
    Kampmann, Peter
    Leebeek, Frank W. G.
    Coppens, Michiel
    Meijer, Karina
    Raheja, Priyanka
    Key, Nigel S.
    Visweshwar, Nathan
    Young, Guy
    Lemons, Richard S.
    Klamroth, Robert
    Miesbach, Wolfgang
    Astermark, Jan
    O'Connell, Niamh
    Kazmi, Rashid Saeed
    Galante, Nicholas
    LeQuellec, Sandra
    Monahan, Paul
    Hermans, Cedric R.
    BLOOD, 2023, 142
  • [50] Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
    Liu, Guoqing
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Li, Zhengping
    Chen, Zhenping
    Wu, Runhui
    FRONTIERS IN PEDIATRICS, 2022, 10
12345